Kausik K Ray MBChB, MD, MPhil, FRCPProfessor, Professor of Public Health and Consultant Cardiologist, Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, London, UK
Kausik Kumar Ray is currently Professor of Public Heath, Department of Public Health and Primary Care, School of Public Health, Imperial College London. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and European Atherosclerosis Society also serving on the EAS Consensus panel. Professor Ray has been the national lead investigator (SC or EC member) for several major medical trials, and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS.
Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 49 and i10 of 86 and more than 23,000 citations overall including publications in NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH and includes 55 countries, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250 000 people in London.
Kausik K Ray has received personal fees (clinical events adjudication committee) from AbbVie, Inc.; consultant fees/honoraria from Aegerion, Algorithm, Amgen, AstraZeneca, Boehringer Ingelheim, Cerenis, Eli Lilly and Company, Esperion, Ionis Pharmaceuticals, Kowa, Medicines Company, MSD, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Resverlogix, Sanofi and Takeda; and research grants from Amgen, Kowa, MSD, Pfizer, Regeneron Pharmaceuticals, Inc. and Sanofi
Recent Contributions to PracticeUpdate:
- Efficacy and Safety of Bempedoic Acid Among Patients With and Without Diabetes
- Efficacy of Inclisiran on Cardiovascular Outcomes
- Effect of Inclisiran on Lipids for Primary Prevention
- Long-Term Absolute Risk for Cardiovascular Disease Stratified by Fasting Glucose Level
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins
- Clinical Efficacy and Safety of Achieving Very Low LDL Cholesterol With the PCSK9 Inhibitor Evolocumab